Rockwell Medical

RMTI · NASDAQ

$7.23−$0.26 (−3.47%)TodayMarket closed · Oct 20, 6:24 PM ET

Prev close $7.49

RMTI analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $20.40 (+182.2% upside)

Low: $20.20
Now: $7.23
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

RMTI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 11, 2026	Maintains	Buy	$20.00	43%
HC Wainwright & Co.	Jul 9, 2026	Maintains	Buy	$2.00 → $20.00	43%
HC Wainwright & Co.	Mar 30, 2026	Maintains	Buy	$2.50 → $2.00	43%
HC Wainwright & Co.	Jan 26, 2026	Maintains	Buy	$2.50	43%
HC Wainwright & Co.	Nov 13, 2025	Maintains	Buy	$3.00 → $2.50	43%

The case for and against

Updated Oct 18, 2026

Bull case

Rockwell Medical is benefiting from renewed listing stability after its 1-for-10 reverse stock split, which helped the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement and removed an overhang on the equity. Operationally, 2Q26 revenue of $17.8M rose 11% year over year, driven by new Western U.S. customers and stronger orders from existing dialysis providers, reinforcing demand for its hemodialysis concentrate portfolio. Despite a wider-than-expected net loss of $0.34 per share, the company ended the midpoint of 2026 with $24.8M in cash, cash equivalents, and marketable securities and generated $2.1M in free cash flow from operations, supporting a constructive outlook.

Bear case

Rockwell Medical is challenged by a valuation that rests on only about $74M of enterprise value against roughly $24M to $25M of cash and $8.7M to $9M of debt, suggesting limited cushion if execution slips. The core bearish case centers on its reliance on market traction and partnerships in a competitive dialysis supply market, where commercial setbacks or weak adoption could quickly pressure growth. In addition, management’s inability to control expenses and the possibility of medium- to long-term equity dilution create further downside risk, especially given the low terminal growth assumption of 1% and the sensitivity of the DCF to share count changes by end-1Q27 or mid-2027.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.